Disease overview Acute myeloid leukemia (AML) is a frequently fatal bone marrow stem cell
cancer characterized by unbridled proliferation of malignant marrow stem cells with …

Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML)
is occurring rapidly. Since 2017, nine agents have been approved for various indications in …

Since the comprehensive recommendations for the management of acute promyelocytic
leukemia (APL) reported in 2009, several studies have provided important insights …

Measurable residual disease (MRD; previously termed minimal residual disease) is an
independent, postdiagnosis, prognostic indicator in acute myeloid leukemia (AML) that is …

Reactive oxygen species (ROS) play a pivotal role in biological processes and continuous
ROS production in normal cells is controlled by the appropriate regulation between the silver …

In 1957, Hillestad et al. defined acute promyelocytic leukemia (APL) for the first time in the
literature as a distinct type of acute myeloid leukemia (AML) with a “rapid downhill course” …

The therapeutic armamentarium of acute myeloid leukemia (AML) has rapidly expanded in
the past few years, driven largely by translational research into its genomic landscape and …

Acute myeloid leukaemia (AML) incidence is age dependent, rising markedly in patients
aged! 60 years. Ageing of the European population may therefore contribute to the reported …

Metastatic tumors are the cause of more than 90% of cancer related deaths. Metastasis
formation can be considered as a culmination of the Darwinian evolutionary process within …

The unraveling of the pathophysiology of acute myeloid leukemia (AML) has resulted in
rapid translation of the information into clinical practice. After more than 40 years of slow …